Dr. Don Eslin

Arnold Palmer Hospital for Children

Dr. Eslin is the managing physician of the Haley Center for Children’s Cancer and Blood Disorders at Arnold Palmer Hospital for Children and is the principal investigator of Beat Childhood Cancer (formerly NMTRC) in Orlando, FL.

Appointments: (321) 841-8588 to schedule.

92 West Miller St., MP318
Orlando, FL 32806
Phone: (321) 841-8588
E-mail: don.eslin@orlandohealth.com

Dr Eslin is the managing physician of the Haley Center for Children’s Cancer and Blood Disorders at Arnold Palmer Hospital for Children and is the principal investigator of Beat Childhood Cancer (formerly NMTRC) in Orlando, FL.

August 1993 – May, 1997	Marshall University School of Medicine, Huntington, WV Doctor of Medicine
July 1997 – June 2000	Arnold Palmer Hospital for Children, Orlando, FL Pediatric Residency
May 2000 – May 2003	Children’s Hospital of Philadelphia, Philadelphia, PA Pediatric Hematology/Oncology Fellowship

Eslin D, Lee C, Sankpal UT, Sholler G, Maliakal P, Sutphin RM, and Basha R. Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study. Tumor Biology: Volume 34, Issue 5 (2013), Page 2781-2789. DOI 10.1007/s13277-013-0836-6

Sankpal1, U.T., Lee, C.M., Connelly, S.F., Kayaleh, O., Eslin, D., Sutphin, R.M., Goodison, S., Adwan, L., Zawia, N.H., Lichtenberger, L., Basha, R. (2013). Cellular and organismal toxicity of the anti-cancer small molecule, tolfenamic acid: A pre-clinical evaluation. Cell Physiol Biochem. 2013; 32(3):675-86. DOI: 10.1159/000354471.

Sholler GL, Gerner EW, Bergendahl G, MacArthur RB, VanderWerff A, Ashikaga T, Bond JP, Ferguson W, Roberts W, Wada RK, Eslin D, Kraveka JM, Kaplan J, Mitchell D, Parikh NS, Neville K, Sender L, Higgins T, Kawakita M, Hiramatsu K, Moriya S, Bachmann AS. A phase I trial of DFMO targeting polyamine addiction in patients with relapsed/refractory neuroblastoma. PlosONE. May 2015 10(5):1-20. DOI:10.1371/0127246

Shelake, S, Eslin, D, Sutphin, RM, Sankpal1, UT, Wadwani, A, Kenyon, LE, Tabor-Simecka, L, Bowman, WP, Vishwanatha, JK, Basha, R. Combination of 13 cis-retinoic acid and tolfenamic acid induces apoptosis and effectively inhibits high-risk neuroblastoma cell proliferation. Int J Dev Neurosci. 46:92-9. doi: 10.1016/j.ijdevneu.2015.07.012. PubMed PMID: 26287661.

Sholler, G., Bond, J., Bergendahl, G., Dragon, J., Neville, K., Ferguson, W., Roberts, W., Eslin, D., Kraveka, J., Kaplan, J., Mitchell, D., Parikh, N., Merchant, M., Ashikaga, T., Hanna, G., Lescault, P. J., Siniard, A., Corneveaux, J., Huentelman, M., Trent, J. Feasibility of Implementing Molecular-Guided Therapy for the Treatment of Patients with Relapsed or Refractory Neuroblastoma. Cancer Medicine, 2015 4(6): 871-886.

Mitchell D, Bergendahl G, Ferguson W, Roberts W, Higgins T, Ashikaga T DeSarno M, Kaplan J, Kraveka J, Eslin D, VanderWerff A, Hanna G, Sholler GS. A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. Pediatric Blood & Cancer 2016: 63: 39-46.